Zoledronic acid treatment for cancerous bone metastases: A phase IV study in Taiwan

Journal of Cancer Research and Therapeutics

Volumn 9, Issue 4, 2013, Pages 653-659

  Chiang, Po Hui ^a   Wang, Hwei Chung ^b   Lai, Yuen Liang ^c   Chen, Shin Cheh ^a   Yen Hwa, Wayne ^d   Kok, Chit Kheng ^e   Ou, Yen Chuan ^f   Huang, Jen Shen ^a   Huang, Tzu Chuan ^g   Chao, Tsu Yi ^h  

^a Chang Gung Medical Foundation   (Australia)

^b China Medical University Hospital   (China)

^c Dept of Radiology Oncology   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^f Tai An Hospital   (Taiwan)

^g TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

bone marker; Bone metastases; osteonecrosis of the jaw; skeletal related event; Zometa

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ALPL PROTEIN, HUMAN; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; IMIDAZOLE DERIVATIVE; ISOENZYME; OSTEOPROTEGERIN; PEPTIDE; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFRSF11B PROTEIN, HUMAN; ZOLEDRONIC ACID;

AGED; ANALGESIA; BLOOD; BONE; BONE NEOPLASMS; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE MYELOMA; PAIN; PATHOLOGY; PHASE 4 CLINICAL TRIAL; PROSTATE TUMOR; SECONDARY; TAIWAN;

ACID PHOSPHATASE; AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; ISOENZYMES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOPROTEGERIN; PAIN; PAIN MANAGEMENT; PEPTIDES; PROSTATIC NEOPLASMS; TAIWAN;

EID: 84894427695     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.126471     Document Type: Article

References (23)

1. Buijs JT, van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett 2009;273:177-93.
2. Lipton A. Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention. J Support Oncol 2004;2:205-13.
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12(20 Pt 2):6243s-9s.
4. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
5. Morris GJ, Mitchell EP. Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. J Natl Med Assoc 2007;99:35-45.
6. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
7. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21.
8. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
9. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35.
10. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005;20:1804-12.
11. Heider UU, Fleissner CC, Zavrski II, Kaiser MM, Hecht MM, Jakob CC, et al. Bone markers in multiple myeloma. Eur J Cancer 2006;42:1544-53.
12. Chao TY, Yu JC, Ku CH, Chen MM, Lee SH, Janckila AJ, et al. Tartrateresistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 2005;11:544-50.
13. Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 2004;9:319-29.
14. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005;10:52-62.
15. Green JRJ, Müller KK, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
16. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonateassociated osteonecrosis of the jaw: A review. J Am Dent Assoc 2009;140:864-75.
17. Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24(Suppl 18S):8528.
18. Polascik TJ, Mouraviev VV. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 2008;4:261-8.
19. Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008;13:911-20.
20. Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 2011;69:e364-71.
21. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36.
22. Terpos E, la Fuente de J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, et al. Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003;106:455-7.
23. Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, et al. Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008;26:2644-52.